138 related articles for article (PubMed ID: 33039483)
41. Erlotinib-induced dermatologic side-effects.
Bovenschen HJ; Alkemade JA
Int J Dermatol; 2009 Mar; 48(3):326-8. PubMed ID: 19261029
[No Abstract] [Full Text] [Related]
42. Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial.
Tsutsui K; Kikuchi K; Nozawa K; Takashima A; Tsuchiyama K; Namikawa K; Aiba S; Yamazaki N
J Dermatol; 2021 Jul; 48(7):1077-1080. PubMed ID: 33682955
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Cancer Med; 2019 Aug; 8(9):4169-4175. PubMed ID: 31199595
[TBL] [Abstract][Full Text] [Related]
44. When bugs and drugs conspire: driving acneiform skin toxicity.
Billi AC; Sarkar MK; Gudjonsson JE
J Clin Invest; 2020 Mar; 130(3):1090-1092. PubMed ID: 32015232
[TBL] [Abstract][Full Text] [Related]
45. Adverse cutaneous effects of neratinib.
Hamid RN; Ahn CS; Huang WW
J Dermatolog Treat; 2019 Aug; 30(5):487-488. PubMed ID: 30321080
[TBL] [Abstract][Full Text] [Related]
46. [Erlotinib-induced acneiform rash not affecting previously irradiated skin].
Eguren C; Domínguez-Fernández I; Santiago-Sánchez-Mateos DI; García-Díez A
Actas Dermosifiliogr; 2010 Mar; 101(2):186-7. PubMed ID: 20223168
[No Abstract] [Full Text] [Related]
47. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
Campbell TM; Brown CW
J Drugs Dermatol; 2008 Dec; 7(12):1161-3. PubMed ID: 19137770
[TBL] [Abstract][Full Text] [Related]
48. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors.
Brodell LA; Hepper D; Lind A; Gru AA; Anadkat MJ
J Cutan Pathol; 2013 Oct; 40(10):865-70. PubMed ID: 23941617
[TBL] [Abstract][Full Text] [Related]
49. Rosaceiform eruption induced by erlotinib.
Patrizi A; Bianchi F; Neri I
Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
[TBL] [Abstract][Full Text] [Related]
50. Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Ann Oncol; 2018 Dec; 29(12):2393-2395. PubMed ID: 30307464
[No Abstract] [Full Text] [Related]
51. Acute acne flare following isotretinoin administration: potential protective role of low starting dose.
Borghi A; Mantovani L; Minghetti S; Virgili A; Bettoli V
Dermatology; 2009; 218(2):178-80. PubMed ID: 19060474
[No Abstract] [Full Text] [Related]
52. Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2.
Zhao Q; Wang YN; Wang B
Jpn J Clin Oncol; 2013 Feb; 43(2):200-4. PubMed ID: 23264674
[TBL] [Abstract][Full Text] [Related]
53. Case of severe acneiform eruptions associated with the BRAF inhibitor vemurafenib.
Ansai O; Fujikawa H; Shimomura Y; Abe R
J Dermatol; 2017 Mar; 44(3):e15-e16. PubMed ID: 27511106
[No Abstract] [Full Text] [Related]
54. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition.
Wollenberg A; Moosmann N; Klein E; Katzer K
Exp Dermatol; 2008 Sep; 17(9):790-2. PubMed ID: 18503553
[TBL] [Abstract][Full Text] [Related]
55. Images in clinical medicine. Cetuximab-associated acneiform eruption.
Moss JE; Burtness B
N Engl J Med; 2005 Nov; 353(19):e17. PubMed ID: 16282170
[No Abstract] [Full Text] [Related]
56. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors.
Alexandrescu DT; Vaillant JG; Dasanu CA
Clin Exp Dermatol; 2007 Jan; 32(1):71-4. PubMed ID: 17034418
[TBL] [Abstract][Full Text] [Related]
57. Acneiform reaction to erlotinib.
Schalock PC; Zug KA
Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
[TBL] [Abstract][Full Text] [Related]
58. Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption.
Kikuchi K; Nozawa K; Yamazaki N; Nakai Y; Higashiyama A; Asano M; Fujiwara Y; Kanda S; Ohe Y; Takashima A; Boku N; Inoue A; Takahashi M; Mori T; Taguchi O; Inoue Y; Mizutani H
J Dermatol; 2019 Jan; 46(1):18-25. PubMed ID: 30402978
[TBL] [Abstract][Full Text] [Related]
59. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.
Van Doorn R; Kirtschig G; Scheffer E; Stoof TJ; Giaccone G
Br J Dermatol; 2002 Sep; 147(3):598-601. PubMed ID: 12207609
[TBL] [Abstract][Full Text] [Related]
60. Acne successfully treated with acitretin in a patient with peanut allergy. Reply.
Walsh SA; Holme SA
Br J Dermatol; 2008 Nov; 159(5):1208-9. PubMed ID: 18795928
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
